New hope for kidney transplant patients: study tests better rejection treatment
NCT ID NCT03737136
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 24 times
Summary
This study tested two different drug combinations to treat a type of kidney transplant rejection called antibody-mediated rejection. Twenty patients who had this rejection were given either a standard treatment or the standard treatment plus an extra drug (bortezomib). The goal was to see which approach better protects the transplanted kidney and improves its function over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANTIBODY-MEDIATED REJECTION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
SBMU
Tehran, Iran
Conditions
Explore the condition pages connected to this study.